Coherus BioSciences (NASDAQ:CHRS) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Coherus BioSciences (NASDAQ:CHRS) in a report issued on Tuesday,Benzinga reports. HC Wainwright currently has a $7.00 target price on the biotechnology company’s stock.

Other equities research analysts also recently issued research reports about the company. StockNews.com downgraded Coherus BioSciences from a “hold” rating to a “sell” rating in a research report on Tuesday, April 15th. UBS Group reiterated a “neutral” rating and issued a $1.05 price target (down previously from $1.50) on shares of Coherus BioSciences in a research report on Thursday, April 24th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $5.26.

Coherus BioSciences Stock Down 3.0 %

Shares of CHRS stock opened at $1.00 on Tuesday. The stock has a 50-day simple moving average of $0.96 and a 200 day simple moving average of $1.12. Coherus BioSciences has a fifty-two week low of $0.66 and a fifty-two week high of $2.43. The stock has a market capitalization of $115.85 million, a P/E ratio of -12.50 and a beta of 1.01.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of Montreal Can acquired a new stake in Coherus BioSciences during the 4th quarter worth about $34,000. Steph & Co. purchased a new position in Coherus BioSciences during the fourth quarter valued at approximately $34,000. Intech Investment Management LLC acquired a new position in Coherus BioSciences in the 4th quarter valued at approximately $38,000. Wealth Enhancement Advisory Services LLC lifted its position in Coherus BioSciences by 97.3% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 30,847 shares of the biotechnology company’s stock worth $43,000 after buying an additional 15,214 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Coherus BioSciences during the 4th quarter valued at $52,000. Hedge funds and other institutional investors own 72.82% of the company’s stock.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.